Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 6, 2005, Pages 605-618

  Mouly, Stéphane J ^b   Matheny, Chris ^b   Paine, Mary F ^b   Smith, Glenn ^b   Lamba, Jatinder ^b   Lamba, Vishal ^b   Pusek, Susan N ^b   Schuetz, Erin G ^b   Stewart, Paul W ^b   Watkins, Paul B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; ERYTHROMYCIN; GLYCOPROTEIN P; SAQUINAVIR;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE LIVER FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; DUODENUM BIOPSY; ENZYME ACTIVITY; FEMALE; FIRST PASS EFFECT; FLUID INTAKE; GENE SEQUENCE; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE CELL; LIVER MICROSOME METABOLISM; LYMPHOCYTE COUNT; MALE; MEDICAL ASSESSMENT; MULTIPLE REGRESSION; NORMAL HUMAN; ORANGE JUICE; PRIORITY JOURNAL; PROTEIN CONTENT; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BEVERAGES; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CITRUS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCYTES; FEMALE; GENE EXPRESSION; GENOTYPE; HALF-LIFE; HEPATOCYTES; HIV PROTEASE INHIBITORS; HUMANS; INTESTINES; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; SAQUINAVIR;

EID: 28844459455     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.08.014     Document Type: Article

References (49)

1. M. Barry, S. Gibbons, D. Back, F. Mulcahy Protease inhibitors in patient with HIV disease. Clinically important pharmacokinetic considerations Clin Pharmacokinet 32 1997 194 209
2. R.M.W. Hoetelmans, P.L. Meenhorst, J.W. Mulder, D.M. Burger, C.H.W. Koks, J.H. Beijnen Clinical pharmacology of HIV protease inhibitors focus on saquinavir, indinavir, and ritonavir Pharm World Sci 19 1997 159 174
3. M.E. Fitzsimmons, J.M. Collins Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism Drug Metab Dispos 25 1997 256 266
4. K.E. Thummel, K.L. Kunze, D.D. Shen Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction Adv Drug Deliv Rev 27 1997 99 127
5. S.A. Wrighton, B.J. Ring, P.B. Watkins, M. Vandenbranden Identification of a polymorphically expressed member of the human cytochrome P450III family Mol Pharmacol 36 1989 97 105
6. S.A. Wrighton, W.R. Brian, M.A. Sari, M. Iwasaki, F.P. Guengerich, J.L. Raucy Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3) Mol Pharmacol 38 1990 207 213
7. K.S. Lown, J.C. Kolars, K.E. Thummel, J.L. Barnett, K.L. Kunze, S.A. Wrighton Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test Drug Metab Dispos 22 1994 947 955
8. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 4 2001 383 391
9. M. Frohlich, M.M. Hoffmann, J. Burhenne, G. Mikus, J. Weiss, W.E. Haefeli Association of the CYP3A5 A6986G (CYP3A5* (*)3) polymorphism with saquinavir pharmacokinetics Br J Clin Pharmacol 58 2004 443 444
10. R.B. Kim, M.F. Fromm, C. Wandel, B. Leake, A.J.J. Wood, D.M. Roden The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors J Clin Invest 101 1998 289 294
11. P.B. Watkins The barrier function of CYP3A4 and P-glycoprotein in the small bowel Adv Drug Deliv Rev 27 1997 161 170
12. V.J. Wacher, J.A. Silverman, Y. Zhang, L.Z. Benet Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics J Pharm Sci 87 1998 1322 1329
13. C.B. Washington, M.M. Wiltshire, M. Man, T. Moy, S.R. Harris, E. Worth The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells Drug Metab Dispos 28 2000 1058 1062
14. M.T. Huisman, J.W. Smit, H.R. Wiltshire, R.M. Hoetelmans, J.H. Beijnen, A.H. Schinkel P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir Mol Pharmacol 59 2001 806 813
15. V.J. Wacher, C.Y. Wu, L.Z. Benet Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein implications for drug delivery and activity in cancer chemotherapy Mol Carcinog 13 1995 129 134
16. S. Mouly, M.F. Paine, P.B. Watkins Contributions of CYP3A4, P-glycoprotein and serum protein binding to the intestinal first-pass extraction of saquinavir J Pharmacol Exp Ther 308 2004 941 948
17. K.S. Lown, R.R. Mayo, A.B. Leichtman, H.L. Hsiao, D.K. Turgeon, P. Schmiedlin-Ren Role of intestinal P-glycoprotein (MDR1) in interpatient variation in the oral bioavailability of ciclosporine Clin Pharmacol Ther 62 1997 248 260
18. D.J. Edwards, M.E. Fitzsimmons, E.G. Schuetz, K. Yasuda, M.P. Ducharme, L.H. Warbasse 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein Clin Pharmacol Ther 65 1999 237 244
19. K.S. Lown, D.G. Bailey, R.J. Fontana, S.K. Janardan, C.H. Adair, L.A. Fortlage Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression J Clin Invest 99 1997 2545 2553
20. P.B. Watkins Noninvasive tests of CYP3A enzymes Pharmacogenetics 4 1994 171 184
21. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J Pharmacol Exp Ther 283 1997 1552 1562
22. S. Mouly, M.F. Paine P-glycoprotein increases from proximal to distal regions of human small intestine Pharm Res 20 2003 1595 1599
23. S. Malhotra, D.G. Bailey, M.F. Paine, P.B. Watkins Seville orange juice-felodipine interaction comparison with dilute grapefruit juice and involvement of furocoumarins Clin Pharmacol Ther 69 2001 14 23
24. P. Schmiedlin-Ren, K.S. Thummel, J.M. Fisher, M.F. Paine, K.S. Lown, P.B. Watkins Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25-dihydroxyvitamin D3 Mol Pharmacol 51 1997 741 754
25. S.M. Kakar, M.F. Paine, P.W. Stewart, P.B. Watkins 6′,7′- Dihydroxybergamottin contributes to the grapefruit juice effect Clin Pharmacol Ther 75 2004 569 579
26. H.L. Lin, U.M. Kent, P.F. Hollenberg The grapefruit juice effect is not limited to P4503A4 evidence for bergamottin-dependent inactivation, heme destruction and covalent binding to protein in P450s 2B6 and 3A5 J Pharmacol Exp Ther 313 2005 154 164
27. D.G. Bailey, G.K. Dresser, J.H. Kreeft, C. Munoz, D.J. Freeman, J.R. Bend Grapefruit-felodipine interaction effect of unprocessed fruit and probable active ingredients Clin Pharmacol Ther 68 2000 468 477
28. D.G. Bailey, J. Malcolm, O. Arnold, J.D. Spence Grapefruit-juice-drug interactions Br J Clin Pharmacol 46 1998 101 115
29. R.B. Parker, C.R. Yates, J.E. Soberman, S.C. Laizure Effect of grapefruit juice on intestinal P-glycoprotein evaluation using digoxin in humans Pharmacotherapy 23 2003 979 987
30. M.F. Paine, S.S. Ludington, M.L. Chen, P.W. Stewart, S.M. Huang, P.B. Watkins Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 33 2005 426 433
31. D. Wagner CYP3A4 and the erythromycin breath test [letter] Clin Pharmacol Ther 64 1998 129 130
32. N.G. Knebel, S.R. Sharp, M.J. Madigan Quantification of the anti-HIV drug saquinavir by high-speed on-line high-performance liquid chromatography/tandem mass spectrometry J Mass Spectrom 30 1995 1149 1156
33. R.J. Farrell, A. Murphy, A. Long, S. Donnelly, A. Cherikuri, D. O'Toole High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy Gastroenterology 118 2000 279 288
34. S. Gupta, S. Gollapudi P-glycoprotein (MDR 1 gene product) in cells of the immune system its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection J Clin Immunol 13 1993 289 301
35. J.K. Lamba, Y.S. Lin, K. Thummel, A. Daly, P.B. Watkins, S. Strom Common allelic variants of cytochrome P4503A4 and their prevalence in different populations Pharmacogenetics 12 2002 121 132
36. H.H.T. Kupferschmidt, K.E. Fattinger, H.R. Ha, F. Follath, S. Krahenbuhl Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man Br J Clin Pharmacol 45 1998 355 359
37. S. Hoffmeyer, O. Burk, O. Von Richter, H.P. Arnold, J. Brockmoller, A. Johne Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478
38. J. Fellay, C. Marzolini, E.R. Meaden, D.J. Back, T. Buclin, J.P. Chave Swiss HIV Cohort Study Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1 a pharmacogenetics study Lancet 359 2002 30 36
39. S. Mouly, K.S. Lown, D. Kornhauser, J.L. Joseph, W.D. Fiske, I.H. Benedek Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans Clin Pharmacol Ther 72 2002 1 9
40. C. Veau, L. Faivre, S. Tardivel, M. Soursac, H. Banide, B. Lacour Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice J Pharmacol Exp Ther 302 2002 742 750
41. H. Gutmann, G. Fricker, J. Drewe, M. Török, S. Michael, C. Beglinger Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake Pharm Res 16 1999 402 407
42. M.T. Huisman, J.W. Smit, K.M. Crommentuyn, N. Zelcer, H.I. Wiltshire, J.H. Beijnen Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs AIDS 16 2002 2295 2301
43. G.C. Williams, A. Liu, G. Knipp, P.J. Sinko Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2) Antimicrob Agents Chemother 46 2002 3456 3462
44. V.J. Palkama, J. Ahonen, P.J. Neuvonen, K.T. Olkkola Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam Clin Pharmacol Ther 66 1999 33 39
45. D.A. Hesselink, R.H.N. Van Schaik, I.P. Van der Heiden, M. Van der Werf, P.J.H. Smak Gregoor, J. Lindemans Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 2003 245 254
46. D.A. Katz, D.R. Grimm, S.C. Cassar, M.C. Gentile, X. Ye, M.J. Rieser CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels Clin Pharmacol Ther 75 2004 516 528
47. S.J. Plummer, D.V. Conti, P.L. Paris, A.P. Curran, G. Casey, J.S. Witte CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer Cancer Epidemiol Biomarkers Prev 12 2003 928 932
48. J.C. Gorski, S. Vannaprasaht, M.A. Hamman, W.T. Ambrosius, M.A. Bruce, B. Haehner-Daniels The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity Clin Pharmacol Ther 74 2003 275 287
49. D.J. McConn, Y.S. Lin, K. Allen, K.L. Kunze, K.E. Thummel Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs Drug Metab Dispos 32 2004 1083 1091